vaccine against the novel coronavirus, Covaxin, has drawn global attention.In a tweet, the ICMR said, "India's indigenous vaccine against #COVID19 Covaxin-a product of ICMR-Bharat Biotech collaboration, achieves remarkable feat.
Data generated from within India underlines impressive safety and immunogenicity profile of Covaxin and sparks Lancet's interest in publishing them."Also Read | The global drive to reimagine capitalismThe ICMR said, "Encouraging Phase I and Phase II COVAXIN trial results have paved the path for Phase III Clinical Trial in India, which is currently ongoing at 22 sites.".